Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2006048225) QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2006/048225 International Application No.: PCT/EP2005/011662
Publication Date: 11.05.2006 International Filing Date: 31.10.2005
IPC:
A61K 31/439 (2006.01) ,C07D 453/02 (2006.01) ,A61P 29/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
439
the ring forming part of a bridged ring system, e.g. quinuclidine
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
453
Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
02
containing not further condensed quinuclidine ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
Applicants:
NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basl, CH (AE, AG, AL, AM, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, MG, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SY, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW)
NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59 A-1230 Vienna, AT (AT)
PRESS, Neil, John [GB/GB]; GB (UsOnly)
COLLINGWOOD, Stephen, Paul [GB/GB]; GB (UsOnly)
BAETTIG, Urs [GB/GB]; GB (UsOnly)
COX, Brian [GB/GB]; GB (UsOnly)
GARAD, Sudhakar, Devidasrao [IN/US]; US (UsOnly)
KIM, Hyungchul [KR/US]; US (UsOnly)
PAPOUTSAKIS, Dimitris [GR/US]; US (UsOnly)
WATSON, Simon, James [GB/GB]; GB (UsOnly)
Inventors:
PRESS, Neil, John; GB
COLLINGWOOD, Stephen, Paul; GB
BAETTIG, Urs; GB
COX, Brian; GB
GARAD, Sudhakar, Devidasrao; US
KIM, Hyungchul; US
PAPOUTSAKIS, Dimitris; US
WATSON, Simon, James; GB
Agent:
GRUBB, Philip; Novartis AG Corporate Intellectual Property CH-4002 Basel, CH
Priority Data:
0424284.802.11.2004GB
Title (EN) QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
(FR) DERIVES DE LA QUINUCLIDINE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RECEPTEUR M3 MUSCARINIQUE
Abstract:
(EN) Compounds of Formula (I) ; in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
(FR) L'invention concerne des composés de formule (I), se présentant sous la forme d'un sel ou d'un zwittérion. Dans cette formule, R1, R2, R3 et R4 sont spécifiés dans la description, et sont utilisés pour traiter des états pathologiques médiés par le récepteur M3 muscarinique, en particulier les maladies inflammatoires et obstructives des voies respiratoires. L'invention concerne, de plus, des compositions pharmaceutiques qui contiennent les composés et un procédé pour préparer les composés.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
NO20072371MXMX/a/2007/005189KR1020070073849IL182695AR054090MA29080
BRPI0517945PE2006-0609EP2206499EP1811999ZA2007/02772JP2008518890
RU02399620ES2353142US20090048281US20100168132CN101056634CA2583237
PT1811999TN2007000164NZ554302AU2005300710DK1811999ID047.2601
MYPI 20054966IN2750/DELNP/2007